Abbott Laboratories vs. Alnylam Pharmaceuticals, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| ABT | ALNY | |
|---|---|---|
| Market Cap | $176.90 billion | $31.88 billion |
| Revenue (TTM) | $46.59 billion | $4.80 billion |
| Net Income (TTM) | $5.42 billion | $733.11 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | ALNY | |
|---|---|---|
| P/E Ratio | 33.28 | 44.57 |
| Price / Book | 3.42 | 23.54 |
| Price / Sales | 3.80 | 6.64 |
ABT leads on 3 of 3 valuation factors.
Profitability
| ABT | ALNY | |
|---|---|---|
| Net Margin | 11.65% | 15.26% |
| Return on Equity | 10.48% | 54.14% |
ALNY leads on 2 of 2 profitability factors.
Dividend
| ABT | ALNY | |
|---|---|---|
| Dividend Yield | 2.45% | — |
| Payout Ratio | 81.55 | — |
ABT and ALNY split the dividend factors evenly.
Risk & Sentiment
| ABT | ALNY | |
|---|---|---|
| Short Interest | 0.57% | 4.32% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, ALNY overview, ALNY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.